Interestingly, expression of several clock genes is dysregulated in human PDA patient tumors and decreased expression of circadian transcription factor BMAL1 is a predictor of tumor progression, suggesting that metabolic reprogramming in PDA might drive cancer progression in part through dysregulation of the circadian clock (12, 28). The gene discussed is BMAL1; the disease is Patent ductus arteriosus.